EUVIMEDEUVIMED entdecken
Crossref

Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Re-emerging Boron Neutron Capture Therapy Field

Arthur Raitano iD, Tioga Martin, Chunying Zhang, Maria-Christina Malinao, Linnette Capo, Maki Ikeura, Rebecca Carroll, Jason C Quintana, Samkeliso Dlamini, Leila Kulenovic, Eva Jahanshir, Sohye Kang und 3 weitere

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c01265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Arthur Raitano und 14 weiteren Autor:innen. Beteiligte Einrichtung: Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States. Hauptthemen laut MEDLINE: Amino Acids, Boron Neutron Capture Therapy. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Boron neutron capture therapy (BNCT) is a re-emerging binary cellular level cancer intervention that occurs through the interaction of a cancer-specific 10boron (10B) drug and neutrons. We created a new 10B drug, 3-borono-l-tyrosine (BTS), that improves on the characteristics of the main historical BNCT drug 4-borono-l-phenylalanine (BPA). BTS has up to 4 times greater uptake in vitro than BPA and increased cellular retention. Like BPA, BTS uptake is mediated by the l-type amino acid transporter-1 (LAT1) but is less sensitive to natural amino acid competition. BTS can be formulated and bolus dosed at much higher levels than BPA, resulting in 2-3 times greater boron delivery in vivo. Fast blood clearance and greater tumor boron delivery result in superior tumor-to-blood ratios. BTS boron delivery appears to correlate with LAT1 expression. BTS is a promising boron delivery drug that has the potential to improve modern BNCT interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amino AcidsBoron Neutron Capture TherapyCell Line, TumorBoronSolubilityPhenylalanineBoron Compounds

Substanzen

Amino AcidsBoronPhenylalanineBoron Compounds

Autor:innen und Institutionen

  • Drug Development Division, TAE Life Sciences, 1756 Cloverfield Boulevard, Santa Monica, California 90404, United States.

ORCID-Profile: Arthur Raitano

Zitieren

APA

Raitano, A., Martin, T., Zhang, C., Malinao, M. C., Capo, L., Ikeura, M., Carroll, R., Quintana, J. C., Dlamini, S., Kulenovic, L., Jahanshir, E., Kang, S., Morrison, K., Torgov, M., & Morrison, K. (2023). Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Re-emerging Boron Neutron Capture Therapy Field. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01265

Vancouver

Raitano A, Martin T, Zhang C, Malinao MC, Capo L, Ikeura M, et al. Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Re-emerging Boron Neutron Capture Therapy Field. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01265

BibTeX
@article{Raitano2023,
  author = {Raitano, Arthur and Martin, Tioga and Zhang, Chunying and Malinao, Maria-Christina and Capo, Linnette and Ikeura, Maki and Carroll, Rebecca and Quintana, Jason C and Dlamini, Samkeliso and Kulenovic, Leila and Jahanshir, Eva and Kang, Sohye and Morrison, Karen and Torgov, Michael and Morrison, Kendall},
  title = {Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Re-emerging Boron Neutron Capture Therapy Field},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c01265}
}
Kostenlos starten →